丁苯酞、紫杉醇联合复方氯化钠对脑梗死合并卵巢癌患者临床疗效观察

Clinical observation on the efficacy of butylphthalide,paclitaxel combined with compound sodium chloride in patients with cerebral infarction and ovarian cancer

目的观察丁苯酞、紫杉醇联合复方氯化钠对脑梗死合并卵巢癌患者临床疗效。方法回顾性选取2019年4月至2021年12月陕西省人民医院神经内科收治的80例脑梗死合并卵巢癌患者作为研究对象。按照治疗手段的不同将患者分为对照组和研究组,各40例。对照组患者给予常规基础脑梗死药物对症治疗,研究组患者在对照组的基础上给予丁苯酞、紫杉醇联合复方氯化钠治疗,治疗14 d。比较两组患者治疗后氧化应激指标[超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSP-Px)、血管紧张素Ⅱ(AngⅡ)]、美国国立卫生研究院卒中量表(NIHSS)评分[8]、改良Rankin量表(MRS)、偏瘫、共济失调、感觉障碍等情况,观察两组患者治疗后生活质量评分改善情况,并观察两组患者不良反应情况。结果治疗后,研究组的SOD、AngⅡ水平分别为(52.36±4.38)U/mL、(131.16±9.15)mmol/L,均明显低于对照组[(77.19±4.69)U/mL、(198.43±9.01)mmol/L],GSH-Px水平为(54.15±5.16)U/L,明显高于对照组[(34.52±5.06)U/L],差异均有统计学意义(P<0.05)。治疗后,研究组NIHSS评分、MRS评分、共济失调、感觉障碍等症状患者比率分别为(2.20±0.89)分、(0.80±0.03)分、1.25%、15.00%、7.50%,均明显低于对照组[(4.21±1.09)分、(2.59±0.88)分、5.00%、32.50%、16.00%],差异均有统计学意义(P<0.05)。研究组患者治疗后生活质量各项指标均明显高于对照组,差异均有统计学意义(P<0.05)。两组用药安全性比较,差异无统计学意义(P>0.05)。结论丁苯酞、紫杉醇联合复方氯化钠治疗脑梗死合并卵巢癌可以明显改善患者临床症状,并有效调节患者氧化应激指标,治疗患者脑梗死症状的同时,提高患者生活质量,对脑梗死治疗及预后均有调节作用,值得临床推广。

Objective To observe the clinical efficacy of butylphthalide,paclitaxel,and compound sodium chloride in the treatment of patients with cerebral infarction and ovarian cancer.Methods Eighty patients with ovarian cancer complicated with cerebral infarction admitted to the Department of Neurology of Shaanxi Provincial People's Hospital from April 2019 to December 2021 were retrospectively selected as the study objects.According to different treatment methods,the patients were divided into control group and study group,with 40 cases in each group.The control group was given symptomatic treatment with conventional basic cerebral infarction drugs,while the research group was given butylphthalide combined with paclitaxel and compound sodium chloride for 14 days on the basis of the control group.The oxidative stress indicators[superoxide dismutase(SOD),glutathione peroxidase(GSP-Px),angiotensin Ⅱ(AngⅡ)],National Institute of Health stroke scale(NIHSS)score,modified Rankin scale(MRS)score,hemiplegia,ataxia,sensory disturbance,etc.after treatment were compared between the two groups,and the improvement of the quality of life score of the two groups of patients after treatment was observed,and the adverse reactions was observed in both groups of patients.Results After treatment,the levels of SOD and AngⅡ in the study group were(52.36±4.38)U/mL and(131.16±9.15)mmol/L,which were significantly lower than those in the control group[(77.19±4.69)U/mL and(198.43±9.01)mmol/L],and the level of GSH-Px was(54.15±5.16)U/L,which was significantly higher than that in the control group[(34.52±5.06)U/L],the differences were statistically significant(P<0.05).After treatment,the rates of patients with symptoms such as NIHSS score,MRS score,ataxia,and sensory disorders in the study group were(2.20±0.89)points,(0.80±0.03)points,1.25%,15.00%,and 7.50%,respectively,which were significantly lower than those in the control group[(4.21±1.09)points,(2.59±0.88)points,5.00%,32.50%,and 16.00%],the differences were statistically significant(P<0.05).The quality of life indicators of the study group patients after treatment were significantly higher than those of the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in drug safety between the two groups(P>0.05).Conclusion Butylphthalide combined with paclitaxel and compound sodium chloride in the treatment of cerebral infarction with ovarian cancer can significantly improve the clinical symptoms of patients,and effectively regulate the oxidative stress indicators of patients.While treating the symptoms of cerebral infarction,it can enhance the quality of life of patients,and has a regulatory effect on the treatment and prognosis of cerebral infarction,which is worthy of clinical promotion.